DTG
Transitions From Daily Dovato to Long-Acting Cabenuva Wanted by Patients With HIV
Many people with HIV want to transition from viral suppression with daily oral Dovato to long-acting injectable ...
JULY 23, 2025
New Studies Show Neural Tube Risk With Dolutegravir Lower Than Thought
WHO updated its global HIV treatment recommendations based on new data showing that even though dolutegravir during ...
JULY 24, 2019
Dolutegravir Maintains Virologic Suppression in Multiple Trials
Dolutegravir-based regimens provide long-term suppression in HIV patients, according to presentations at the 22nd ...
JULY 26, 2018
Load more